Results 161 to 170 of about 23,073,058 (182)

Economic Factors Associated with AI Adoption in Oncology: Cost-Effectiveness Perceptions, Reimbursement Readiness, and Return-on-Investment Confidence Among Romanian Healthcare Professionals. [PDF]

Healthcare (Basel)
Negoiță DC, Stanga L, Branea HS, Roșca CI, Ilie AC, Rosca O.   +5 more
europepmc   +1 more source

What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?

Expert Review of Pharmacoeconomics and Outcomes Research, 2020
Introduction: The statistical quality of many trial-based economic evaluations is poor. When conducting trial-based economic evaluations, researchers often turn to national pharmacoeconomic guidelines for guidance.
Judith E Bosmans, Johanna Maria van Dongen, Mohamed El Alili   +2 more
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Current Development and Practice of Pharmacoeconomic Evaluation Guidelines for Universal Health Coverage in China

Value in Health Regional Issues, 2021
Jeff J Guo, Xiaomeng Yue
exaly  

People also looked at

Frontiers in Public Health, 2021
Ming Hu
exaly  

How Should We Deal with Patient Heterogeneity in Economic Evaluation: A Systematic Review of National Pharmacoeconomic Guidelines

Value in Health, 2013
Bram Ramaekers, Janneke Grutters, Manuela A Joore   +2 more
exaly  

Guidance Document: Global Pharmacoeconomic Model Adaption Strategies

Value in Health Regional Issues, 2014
Shanlian Hu, C Daniel Mullins
exaly  

Evaluation and review of pharmacoeconomic models

Expert Opinion on Pharmacotherapy, 2004
Joel W Hay
exaly  

Microcosting versus DRGs in the provision of cost estimates for use in pharmacoeconomic evaluation

Expert Review of Pharmacoeconomics and Outcomes Research, 2002
Máirín Ryan, Michael Barry
exaly